China is a high incidence of gastric cancer, and in order to understand what kind of treatment is the most effective, in August 3rd, the author conducted a survey interview. In recent years, anti angiogenesis targeted therapy has made remarkable achievements in the treatment of some solid tumors, which can help improve the quality of life and prolong the life of patients.
Health department's latest survey data show that the 5 year survival rate of gastric cancer is less than 20%. The reason is that the traditional gastric cancer treatment can not completely meet the needs of patients with advanced gastric cancer, especially after the failure of the standard treatment, because of the lack of evidence-based medicine, the survival of patients with advanced gastric cancer is less than 12 months.
Due to the tumor growth needs blood to provide nutrition, angiogenesis is critical for tumor growth and metastasis of, if there is no blood with oxygen and nutrients, tumor will starve. " In view of this, anti tumor vascular targeting therapy for advanced gastric cancer has brought a new "dawn", this is the real secret of anti tumor vascular targeting therapy.
Apatinib is vascular endothelial growth factor receptor (VEGFR-2) small molecule tyrosine kinase inhibitors. The ATP binding site of VEGFR-2 in the cell is highly selective, blocking the signal transduction and inhibiting the formation of tyrosine kinase, which can inhibit the formation of new blood vessels in tumor tissues, and ultimately achieve the goal of "starving" tumor. APA imatinib is chemotherapy for advanced gastric cancer standard after the failure of the only proven effective small molecules that target to the drug can significantly prolong the survival time of patients with advanced gastric cancer patients. At the same time, as the area of oral drugs, apatinib can greatly improve patients' compliance.
A patient in a hospital in Shandong province after 2 years of surgery for gastric cancer, and found that ovarian metastasis. In the 6 months after the resection of the metastatic lesions, the intestinal obstruction and the abdominal cavity of the gastric cancer were spread and metastasis, which was a serious threat to the survival. But in colostomy after the third line treatment due to the timely use of APA erlotinib monotherapy target to treatment, the treatment period has a significant effect, safety. After treatment, the patient's situation has been significantly improved, more than half a year later, the patient has basically returned to normal life.
As anti angiogenic agents generated, APA imatinib future also in-depth study of gastric cancer, explore its in the treatment of advanced gastric cancer from three lines mentioned line or even a glimmer of the feasibility. In addition, further research in the field of liver tumor, lung cancer, breast cancer and colorectal cancer is also in clinical trials.